About VistaGen Therapeutics, Inc.
https://www.vistagen.comVistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS).
CEO
Shawn K. Singh
Compensation Summary
(Year 2025)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-06-07 | Reverse | 1:30 |
| 2014-08-18 | Reverse | 1:20 |
ETFs Holding This Stock
Summary
Showing Top 3 of 17
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
JANUS HENDERSON GROUP PLC
Shares:4.17M
Value:$2.92M
ORBIMED ADVISORS LLC
Shares:3.06M
Value:$2.15M
TCG CROSSOVER MANAGEMENT, LLC
Shares:2.68M
Value:$1.88M
Summary
Showing Top 3 of 65
About VistaGen Therapeutics, Inc.
https://www.vistagen.comVistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS).
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2026 | $258K ▲ | $20.31M ▲ | $-19.42M ▼ | -7.53K% ▼ | $-0.54 ▼ | $-19.23M ▼ |
| Q1-2026 | $244K ▲ | $15.88M ▲ | $-15.1M ▼ | -6.19K% ▼ | $-0.47 ▼ | $-14.93M ▼ |
| Q4-2025 | $-15K ▼ | $14.48M ▼ | $-13.63M ▲ | 90.9K% ▲ | $-0.44 ▲ | $-14.33M ▲ |
| Q3-2025 | $234K ▲ | $15.35M ▲ | $-14.09M ▼ | -6.02K% ▲ | $-0.46 ▼ | $-14.96M ▼ |
| Q2-2025 | $183K | $14.41M | $-12.96M | -7.08K% | $-0.42 | $-14.07M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2026 | $77.17M ▲ | $80.93M ▲ | $14.59M ▲ | $66.34M ▲ |
| Q1-2026 | $63.18M ▼ | $68.92M ▼ | $12.16M ▼ | $56.77M ▼ |
| Q4-2025 | $80.48M ▼ | $84.34M ▼ | $13.95M ▲ | $70.39M ▼ |
| Q3-2025 | $88.56M ▼ | $92.31M ▼ | $11.19M ▲ | $81.12M ▼ |
| Q2-2025 | $97.58M | $102.5M | $9.52M | $92.97M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2026 | $-19.42M ▼ | $-13.76M ▲ | $-94K ▲ | $27.65M ▲ | $13.8M ▲ | $-13.82M ▲ |
| Q1-2026 | $-15.1M ▼ | $-18.85M ▼ | $-788K ▼ | $1.49M ▼ | $-18.15M ▼ | $-18.85M ▼ |
| Q4-2025 | $-13.63M ▲ | $-10.06M ▲ | $527K ▲ | $1.95M ▲ | $-7.58M ▲ | $-10.15M ▲ |
| Q3-2025 | $-14.09M ▼ | $-10.28M ▲ | $-422K ▲ | $1.17M ▲ | $-9.53M ▲ | $-10.28M ▲ |
| Q2-2025 | $-12.96M | $-10.89M | $-7.79M | $0 | $-18.67M | $-10.84M |
Revenue by Products
| Product | Q2-2023 | Q3-2023 | Q4-2023 | Q1-2024 |
|---|---|---|---|---|
 License | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Shawn K. Singh
Compensation Summary
(Year 2025)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-06-07 | Reverse | 1:30 |
| 2014-08-18 | Reverse | 1:20 |
ETFs Holding This Stock
Summary
Showing Top 3 of 17
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
JANUS HENDERSON GROUP PLC
Shares:4.17M
Value:$2.92M
ORBIMED ADVISORS LLC
Shares:3.06M
Value:$2.15M
TCG CROSSOVER MANAGEMENT, LLC
Shares:2.68M
Value:$1.88M
Summary
Showing Top 3 of 65